Testosterone regulates Alzheimer's disease pathogenesis

Hormones, Cognition and Dementia: State of The Art and Emergent Therapeutic Strategies

Volumn , Issue , 2009, Pages 242-249

  Pike, Christian J ^a   Rosario, Emily R ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84927029810     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511635700.026     Document Type: Chapter

References (51)

1. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev. 2005; 26(6):833-76.
2. Morley JE. Androgens and aging. Maturitas. 2001; 38(1):61-71; discussion 3.
3. Pike CJ, Rosario ER, Nguyen TV. Androgens, aging, and Alzheimer’s disease. Endocrine. 2006; 29(2): 233-41.
4. Rosario ER, Pike CJ. Androgen regulation of beta- amyloid protein and the risk of Alzheimer’s disease. Brain Res Rev. 2008; 57(2):444-53.
5. Hogervorst E, Combrinck M, Smith AD. Testosterone and gonadotropin levels in men with dementia. Neuroendocrinol Lett. 2003; 24(3/4):203-8.
6. Hogervorst E, Williams J, Budge M, et al. Serum total testosterone is lower in men with Alzheimer’s disease. Neuroendocrinol Lett. 2001; 22(3):163-8.
7. Pennanen C, Laakso MP, Kivipelto M, Ramberg J, Soininen H. Serum testosterone levels in males with Alzheimer’s disease. J Neuroendocrinol. 2004; 16(2):95-8.
8. Moffat SD, Zonderman AB, Metter EJ, et al. Free testosterone and risk for Alzheimer disease in older men. Neurology. 2004; 62(2):188-93.
9. Rosario ER, Chang L, Stanczyk FZ, Pike CJ. Age- related testosterone depletion and the development of Alzheimer disease. JAMA. 2004; 292(12):1431-2
10. MacLusky NJ, Hajszan T, Prange-Kiel J, Leranth C. Androgen modulation of hippocampal synaptic plasticity. Neuroscience. 2006; 138(3):957-65
11. Galea LA. Gonadal hormone modulation of neurogenesis in the dentate gyrus of adult male and female rodents. Brain Res Rev. 2008; 57(2):332-41.
12. Pike CJ, Nguyen TV, Ramsden M, et al. Androgen cell signaling pathways involved in neuroprotective actions. Horm Behav. 2008; 53(5):693-705.
13. Ramsden M, Shin TM, Pike CJ. Androgens modulate neuronal vulnerability to kainate lesion. Neuroscience. 2003; 122(3):573-8.
14. Papasozomenos SC, Papasozomenos T. Androgens prevent the heat shock-induced hyperphosphorylation but not dephosphorylation of tau in female rats. Implications for Alzheimer’s disease. J Alzheimers Dis. 1999; 1(3):147-53.
15. Hardy J. Alzheimer’s disease: the amyloid cascade hypothesis: an update and reappraisal. J Alzheimers Dis. 2006; 9(3 Suppl):151-3.
16. Almeida OP, Flicker L. Testosterone and dementia: too much ado about too little data. J Br Menopause Soc. 2003; 9(3):107-10.
17. Gandy S, Almeida OP, Fonte J, et al. Chemical andropause and amyloid-beta peptide. JAMA. 2001; 285(17):2195-6.
18. Gillett MJ, Martins RN, Clarnette RM, et al. Relationship between testosterone, sex hormone binding globulin and plasma amyloid beta peptide 40 in older men with subjective memory loss or dementia. J Alzheimers Dis. 2003; 5(4):267-9.
19. Ramsden M, Nyborg AC, Murphy MP, et al. Androgens modulate beta-amyloid levels in male rat brain. J Neurochem. 2003; 87(4):1052-5.
20. Rosario ER, Carroll JC, Oddo S, LaFerla FM, Pike CJ. Androgens regulate the development of neuropathology in a triple transgenic mouse model of Alzheimer’s disease. J Neurosci. 2006; 26(51): 13384-9.
21. Gouras GK, Xu H, Gross RS, et al. Testosterone reduces neuronal secretion of Alzheimer’s beta- amyloid peptides. Proc Natl Acad Sci USA. 2000; 97(3):1202-5.
22. Yao M, Nguyen TV, Rosario ER, Ramsden M, Pike CJ. Androgens regulate neprilysin expression: role in reducing beta-amyloid levels. J Neurochem 2008.
23. Azcoitia I, Sierra A, Veiga S, Garcia-Segura LM. Aromatase expression by reactive astroglia is neuroprotective. Ann N YAcad Sci. 2003; 1007:298-305.
24. Xu H, Wang R, Zhang YW, Zhang X. Estrogen, beta-amyloid metabolism/trafficking, and Alzheimer’s disease. Ann N Y Acad Sci. 2006; 1089:324-42.
25. Goodenough S, Engert S, Behl C. Testosterone stimulates rapid secretory amyloid precursor protein release from rat hypothalamic cells via the activation of the mitogen-activated protein kinase pathway. Neurosci Lett. 2000; 296(1):49-52.
26. Bowen RL, Isley JP, Atkinson RL. An association of elevated serum gonadotropin concentrations and Alzheimer disease? J Neuroendocrinol. 2000; 12(4): 351-4.
27. Casadesus G, Webber KM, Atwood CS, et al. Luteinizing hormone modulates cognition and amyloid-beta deposition in Alzheimer APP transgenic mice. Biochim Biophys Acta. 2006; 1762(4):447-52.
28. Bowen RL, Verdile G, Liu T, et al. Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-beta precursor protein and amyloid-beta deposition. J Biol Chem. 2004; 279(19):20539-45.
29. Gharib SD, Wierman ME, Shupnik MA, Chin WW. Molecular biology of the pituitary gonadotropins. Endocr Rev. 1990; 11(1):177-99.
30. Hersh LB, Rodgers DW. Neprilysin and amyloid beta peptide degradation. Curr Alzheimer Res. 2008; 5(2):225-31.
31. Janowsky JS. The role of androgens in cognition and brain aging in men. Neuroscience. 2006; 138(3): 1015-20.
32. Cherrier MM, Craft S, Matsumoto AH. Cognitive changes associated with supplementation of testosterone or dihydrotestosterone in mildly hypogonadal men: a preliminary report. J Androl. 2003; 24(4):568-76.
33. Janowsky JS, Oviatt SK, Orwoll ES. Testosterone influences spatial cognition in older men. Behav Neurosci. 1994; 108(2):325-32.
34. Moffat SD, Zonderman AB, Metter EJ, et al. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab. 2002; 87(11):5001-7.
35. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA. 2008; 299(1):39-52.
36. Haren MT, Wittert GA, Chapman IM, Coates P, Morley JE. Effect of oral testosterone undecanoate on visuospatial cognition, mood and quality of life in elderly men with low-normal gonadal status. Maturitas. 2005; 50(2):124-33.
37. Maki PM, Ernst M, London ED, et al. Intramuscular testosterone treatment in elderly men: evidence of memory decline and altered brain function. J Clin Endocrinol Metab. 2007; 92(11):4107-14.
38. Cherrier MM, Matsumoto AM, Amory JK, et al. Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology. 2005; 64(12):2063-8.
39. Tan RS, Culberson JW. An integrative review on current evidence of testosterone replacement therapy for the andropause. Maturitas. 2003; 45(1):15-27.
40. Lu PH, Masterman DA, Mulnard R, et al. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch Neurol. 2006; 63(2):177-85.
41. Green HJ. Altered cognitive function in men treated for prostate cancer with luteinizing hormonereleasing analogues and cyproterone acetate: a randomized controlled trial. BJU International. 2002; 90(4):427-32.
42. Salminen EK, Portin RI, Koskinen A, Helenius H, Nurmi M. Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clin Cancer Res. 2004; 10(22):7575-82.
43. Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 2008; 300(2):173-81.
44. Fleshner N, Zlotta AR. Prostate cancer prevention: past, present, and future. Cancer. 2007; 110(9): 1889-99.
45. Wilson EM, French FS. Binding properties of androgen receptors. Evidence for identical receptors in rat testis, epididymis, and prostate. J Biol Chem. 1976; 251(18):5620-9.
46. Ostrowski J, Kuhns JE, Lupisella JA, et al. Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats. Endocrinology. 2007; 148(1):4-12.
47. Shao TC, Li HL, Kasper S, et al. Comparison of the growth-promoting effects of testosterone and 7-alpha- methyl-19-nor-testosterone (MENT) on the prostate and levator ani muscle of LPB-tag transgenic mice. Prostate. 2006; 66(4):369-76.
48. Venken K, Boonen S, Van Herck E, et al. Bone and muscle protective potential of the prostate-sparing synthetic androgen 7alpha-methyl-19-nortestosterone: evidence from the aged orchidectomized male rat model. Bone. 2005; 36(4):663-70.
49. von Eckardstein S, Noe G, Brache V, et al. A clinical trial of 7 alpha-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. J Clin Endocrinol Metab. 2003; 88(11): 5232-9.
50. Gao W, Reiser PJ, Coss CC, et al. Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology. 2005; 146(11):4887-97.
51. Rosario ER, Chang L, Head EH, Stanczyk FZ, Pike CJ. Brain levels of sex steroid hormones in men and women during normal aging and in Alzheimer’s disease. Neurobiol Aging, 2009 May 8 [Epub ahead of print].